Aerodynamic characteristics of a dry powder inhaler at low inhalation flows using a mixing inlet with an Andersen Cascade Impactor

European Journal of Pharmaceutical Sciences

Volumn 39, Issue 5, 2010, Pages 348-354

  Nadarassan, Dinesh Kumar ^a   Assi, Khaled H ^a   Chrystyn, Henry ^b  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

^b UNIVERSITY OF HUDDERSFIELD   (United Kingdom)

Author keywords

Dose emission; Dry powder inhaler; Low inhalation flow; Mixing inlet

Indexed keywords

FORMOTEROL FUMARATE;

AIRWAY DYNAMICS; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRY POWDER; EQUIPMENT DESIGN; FLOW MEASUREMENT; FLOW RATE; INHALATION; INTERMETHOD COMPARISON; PARTICLE SIZE; POWDER INHALER; PRESSURE MEASUREMENT; PRIORITY JOURNAL; VALIDATION STUDY;

ADMINISTRATION, INHALATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; POWDERS; PRESSURE;

EID: 77549083736     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2010.01.002     Document Type: Article

References (27)

1. Al-Showair R.A., Tarsin W.Y., Assi K.H., Pearson S.B., and Chrystyn H. Can all patients with COPD use the correct inhalation flow with all inhalers and does training help?. Respir. Med. 101 (2007) 2395-2401
2. Bisgaard H., Klug B., Sumby B.S., and Burnell P.K.P. Fine particle mass from the Diskus inhaler and Turbuhaler inhaler in children with asthma. Eur. Respir. J. 11 (1998) 1111-1115
3. ®: a comparison with terbutaline sulphate in normal subjects. Eur. Respir. J. 7 (1994) 69-73
4. British Pharmacopoeia (BP). Preparations for Inhalation. Aerodynamic Assessment of Fine Particles-Fine Particle Dose and Particle Size Distribution (Ph. Eur. Method 2.9.18) (2005), British Pharmacopoeia pp. A277-A290
5. Broeders M.E.A.C., Molema J., Hop W.C.J., and Folgering H.Th.M. Inhalation profiles in asthmatics and COPD patients: reproducibility and effects of instruction. J. Aerosol Med. 16 (2003) 131-141
6. Broeders M.E., Molema J., Hop W.C., Vermue N.A., and Folgering H.T. The course of inhalation profiles during an acute exacerbation of obstructive lung disease. Respir. Med. 98 (2004) 1173-1179
7. Chodosh S., Flanders J.S., Kesten S., Serby C.W., Hochrainer D., and Witek Jr. T.J. Effective delivery of particles with the HandiHaler dry powder inhalation system over a range of chronic obstructive pulmonary disease severity. J. Aerosol Med. 14 (2001) 309-315
8. Clark A.R., and Hollingworth A.M. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers-implications for in vitro testing. J. Aerosol Med. 6 (1993) 99-110
9. European Pharmacopoeia (EP). 2.9.18 Preparation for Inhalation: Aerodynamic Assessment of Fine Particles. 5.0 edition (2005), European Pharmacopoeia pp. 245-253
10. Everard M.L., Devadason S.G., and Souëf P.N.L. Flow early in the inspiratory manoeuvre affects the aerosol particle size distribution from a Turbuhaler. Respir. Med. 91 (1997) 624-628
11. Hill L.S., and Slater A.L. A comparison of the performance of two modern multidose dry powder asthma inhalers. Respir. Med. 92 (1998) 105-110
12. Hindle M., and Byron P.R. Dose emission from marketed dry powder inhalers. Int. J. Pharm. 116 (1995) 169-177
13. Hinds W.C.L. Aerosol Technology: Properties, Behaviour, and Measurement of Airborne Particles. 2nd edition (1999), Wiley-Interscience, NY, USA
14. Kamin W.E., Genz T., Roeder S., Scheuch G., Trammer T., Juenemann R., and Cloes R.M. Mass output and particle size distribution of glucocorticosteroids emitted from different inhalation devices depending on various inspiratory parameters. J. Aerosol Med. 15 (2002) 65-73
15. Marple V.A., Olson B.A., Santhanakrishan K., Mitchell J.P., Murray S.C., and Hudson-Curtis B.L. Next Generation Pharmaceutical Impactor (a new impactor for pharmaceutical inhaler testing). Part II: Archival calibration. J. Aerosol. Med. 16 (2003) 301-324
16. Marple V.A., Olson B.A., Santhanakrishan K., Roberts D.L., Mitchell J.P., and Hudson-Curtis B.L. Next Generation Pharmaceutical Impactor: A new impactor for pharmaceutical inhaler testing. Part III. Extension of archival calibration to 15 L/min. J. Aerosol. Med. 17 (2004) 335-343
17. Miler N.C., Maniaci M.J., Dwivedi S., and Ward G.W. Aerodynamic sizing with simulated inhalation profiles: total dose capture and measurement. In: Dalby R.N., Byron P.R., Farr S.J., and Peart J. (Eds). Respiratory Drug Delivery VII vol. 1 (2000), Serentec Press, Raleigh, NC 191-196
18. Mitchell J.P., and Nagel N.W. Cascade impactors for the size characterization of aerosols from medical inhalers: their uses and limitation. J. Aerosol Med. 16 (2003) 341-376
19. Newman S.P., Morén F., Trofast E., Talaee N., and Clarke S.W. Terbutaline sulphate Turbuhaler: effect of inhaled flow rate on drug deposition and efficacy. Int. J. Pharm. 74 (1991) 209-213
20. Oort M.V. In vitro testing of dry powder inhalers. Aerosol Sci. Technol. 22 (1995) 364-373
21. Palander A., Mattila T., Karku M., and Muttonen E. In vitro comparison of three salbutamol-containing multidose dry powder inhalers. Clin. Drug Invest. 20 (2000) 25-33
22. Pedesen S. How to use a Rotahaler. Arch. Dis. Child. 61 (1986) 11-14
23. Pedersen S., Hansen O.R., and Fuglsang G. Influence of inspiratory flow rate upon the effect of a Turbuhaler. Arch. Dis. Child. 65 (1990) 308-319
24. Ross D., and Schultz R. Effect of inhalation flow rate on the dosing characteristics of dry powder inhaler (DPI) and metered dose inhaler (MDI) products. J. Aerosol (1996)
25. Tarsin W., Assi K.H., and Chrystyn H. In-vitro inhalation flow rate dependent dosage emission from a combination of budesonide and eformoterol in a dry powder inhaler. J. Aerosol Med. 17 (2004) 25-32
26. Tarsin W.Y., Pearson S.B., Assi K.H., and Chrystyn H. Emitted dose estimates from Seretide Diskus and Symbicort Turbuhaler following inhalation by severe asthmatics. Int. J. Pharm. 316 (2006) 131-137
27. United States Pharmacopeia (USP). Aerosols, Nasal Sprays, Metered Dose Inhalers and Dry Powder Inhalers vol. 28 (2005), The United States Pharmacopeia pp. 2359-2377